Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: How can CATIE inform clinicians?

International Journal of Clinical Practice

Volumn 60, Issue 8, 2006, Pages 933-940

  Citrome, Leslie ^a,c   Stroup, T Scott ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Antipsychotic; Effectiveness; Number needed to treat; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; BODY WEIGHT DISORDER; CALCULATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA EXTRACTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; METABOLIC DISORDER; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PUBLICATION; SCHIZOPHRENIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33746115248     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01044.x     Document Type: Article

References (15)

1. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
2. McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600-10.
3. Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163: 611-22.
4. Pinson L, Gray GE. Number needed to treat: An underused measure of treatment effect. Psychiatr Serv 2003; 54: 145-6, 154.
5. Citrome L. Relatively speaking, how odd can hazards be? Interpreting the odds ratio. PsychEdUp 2005; 1: 2-3.
6. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006 June 1; 59: 990-6. Epub 2005 Dec 20.
7. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997; 126: 712-20.
8. Crowley PA. Antenatal corticosteroid therapy: A meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 1995; 173: 322-34.
9. Dalton GW, Keating JL. Number needed to treat: A statistic relevant for physical therapists. Phys Ther 2000; 80: 1214-9.
10. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998; 317: 1309-12.
11. Guyatt GH, Sinclair J, Cook DJ, Glasziou P. Users' guides to the medical literature. XVI. How to use a treatment recommendation. JAMA 1999; 281: 1836-43.
12. Citrome L, Jaffe A. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 2003; 37: 1849-57.
13. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161: 1709-11.
14. Citrome L. Efficacy should drive atypical antipsychotic treatment. BMJ 2003; 326: 283-4.
15. Citrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being ? J Psychopharmacol 2005; 19 (Suppl. 6): 102-9.